Physiological and pathological cardiac hypertrophy

Journal of Molecular and Cellular Cardiology

Volumn 97, Issue , 2016, Pages 245-262

  Shimizu, Ippei ^a   Minamino, Tohru ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Akt; Angiogenesis; Autophagy; Cardiac hypertrophy; Epigenetic modification; Heart failure; Inflammation; Metabolism; MicroRNA

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CALCINEURIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYTOKINE; DNA; FATTY ACID; GLUCOSE; GLUCOSE TRANSPORTER; HISTONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INSULIN RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 6; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PROTEIN KINASE B; PROTEIN KINASE C; SIRTUIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; THYROID HORMONE; THYROID HORMONE RECEPTOR; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; AUTOPHAGY; CARDIAC MUSCLE CELL; DISEASE CLASSIFICATION; DNA MODIFICATION; ENDOTHELIUM CELL; HEART FAILURE; HEART FIBROBLAST; HEART FUNCTION; HEART VENTRICLE HYPERTROPHY; HISTONE MODIFICATION; HUMAN; IMMUNOCOMPETENT CELL; METABOLISM; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CARDIOMEGALY; GENE EXPRESSION REGULATION; NEOVASCULARIZATION (PATHOLOGY); RISK FACTOR;

ANIMALS; AUTOPHAGY; CARDIOMEGALY; GENE EXPRESSION REGULATION; HEART FAILURE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84975223393     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2016.06.001     Document Type: Review

References (288)

1. Shimizu I., Minamino T., Toko H., Okada S., Ikeda H., Yasuda N., et al. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J. Clin. Invest. 2010, 120:1506-1514.
2. Sano M., Minamino T., Toko H., Miyauchi H., Orimo M., Qin Y., et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007, 446:444-448.
3. Paulus W.J., Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 2013, 62:263-271.
4. Janicki J.S., Brower G.L., Gardner J.D., Chancey A.L., Stewart J.A. The dynamic interaction between matrix metalloproteinase activity and adverse myocardial remodeling. Heart Fail. Rev. 2004, 9:33-42.
5. van Heerebeek L., Borbely A., Niessen H.W., Bronzwaer J.G., van der Velden J., Stienen G.J., et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006, 113:1966-1973.
6. Selby D.E., Palmer B.M., LeWinter M.M., Meyer M. Tachycardia-induced diastolic dysfunction and resting tone in myocardium from patients with a normal ejection fraction. J. Am. Coll. Cardiol. 2011, 58:147-154.
7. Kasner M., Westermann D., Lopez B., Gaub R., Escher F., Kuhl U., et al. Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. J. Am. Coll. Cardiol. 2011, 57:977-985.
8. Borbely A., van der Velden J., Papp Z., Bronzwaer J.G., Edes I., Stienen G.J., et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation 2005, 111:774-781.
9. Burchfield J.S., Xie M., Hill J.A. Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation 2013, 128:388-400.
10. Weeks K.L., McMullen J.R. The athlete's heart vs. the failing heart: can signaling explain the two distinct outcomes?. Physiology 2011, 26:97-105.
11. Lyon R.C., Zanella F., Omens J.H., Sheikh F. Mechanotransduction in cardiac hypertrophy and failure. Circ. Res. 2015, 116:1462-1476.
12. Francis G.S., McDonald K.M., Cohn J.N. Neurohumoral activation in preclinical heart failure. Remodeling and the potential for intervention. Circulation 1993, 87:IV90-IV96.
13. Maillet M., van Berlo J.H., Molkentin J.D. Molecular basis of physiological heart growth: fundamental concepts and new players. Nat. Rev. Mol. Cell Biol. 2013, 14:38-48.
14. Schiattarella G.G., Hill J.A. Is inhibition of hypertrophy a good therapeutic strategy in ventricular pressure overload?. Circulation 2015, 131:1435-1447.
15. Heineke J., Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev. Mol. Cell Biol. 2006, 7:589-600.
16. Bernardo B.C., Weeks K.L., Pretorius L., McMullen J.R. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol. Ther. 2010, 128:191-227.
17. Grossman W., Jones D., McLaurin L.P. Wall stress and patterns of hypertrophy in the human left ventricle. J. Clin. Invest. 1975, 56:56-64.
18. Maillet M., van Berlo J.H., Molkentin J.D. Molecular basis of physiological heart growth: fundamental concepts and new players. Nat. Rev. Mol. Cell Biol. 2013, 14:38-48.
19. Shiojima I., Sato K., Izumiya Y., Schiekofer S., Ito M., Liao R., et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J. Clin. Invest. 2005, 115:2108-2118.
20. Belke D.D., Betuing S., Tuttle M.J., Graveleau C., Young M.E., Pham M., et al. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J. Clin. Invest. 2002, 109:629-639.
21. Kim J., Wende A.R., Sena S., Theobald H.A., Soto J., Sloan C., et al. Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy. Mol. Endocrinol. 2008, 22:2531-2543.
22. McMullen J.R., Shioi T., Huang W.Y., Zhang L., Tarnavski O., Bisping E., et al. The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway. J. Biol. Chem. 2004, 279:4782-4793.
23. Stubbe P., Gatz J., Heidemann P., Muhlen A., Hesch R. Thyroxine-binding globulin, triiodothyronine, thyroxine and thyrotropin in newborn infants and children. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 1978, 10:58-61.
24. Kinugawa K., Jeong M.Y., Bristow M.R., Long C.S. Thyroid hormone induces cardiac myocyte hypertrophy in a thyroid hormone receptor alpha1-specific manner that requires TAK1 and p38 mitogen-activated protein kinase. Mol. Endocrinol. 2005, 19:1618-1628.
25. Anderson B.R., Granzier H.L. Titin-based tension in the cardiac sarcomere: molecular origin and physiological adaptations. Prog. Biophys. Mol. Biol. 2012, 110:204-217.
26. Knoll R., Hoshijima M., Hoffman H.M., Person V., Lorenzen-Schmidt I., Bang M.L., et al. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell 2002, 111:943-955.
27. Lyon R.C., Zanella F., Omens J.H., Sheikh F. Mechanotransduction in cardiac hypertrophy and failure. Circ. Res. 2015, 116:1462-1476.
28. Kenessey A., Ojamaa K. Thyroid hormone stimulates protein synthesis in the cardiomyocyte by activating the Akt-mTOR and p70S6K pathways. J. Biol. Chem. 2006, 281:20666-20672.
29. Pantos C., Mourouzis I., Markakis K., Tsagoulis N., Panagiotou M., Cokkinos D.V. Long-term thyroid hormone administration reshapes left ventricular chamber and improves cardiac function after myocardial infarction in rats. Basic Res. Cardiol. 2008, 103:308-318.
30. Ziegelhoffer-Mihalovicova B., Briest W., Baba H.A., Rassler B., Zimmer H.G. The expression of mRNA of cytokines and of extracellular matrix proteins in triiodothyronine-treated rat hearts. Mol. Cell. Biochem. 2003, 247:61-68.
31. Yao J.L., Eghbali M. Decreased collagen gene-expression and absence of fibrosis in thyroid hormone-induced myocardial hypertrophy - response of cardiac fibroblasts to thyroid-hormone invitro. Circ. Res. 1992, 71:831-839.
32. Chang K.C., Figueredo V.M., Schreur J.H., Kariya K., Weiner M.W., Simpson P.C., et al. Thyroid hormone improves function and Ca2+ handling in pressure overload hypertrophy. Association with increased sarcoplasmic reticulum Ca2+-ATPase and alpha-myosin heavy chain in rat hearts. J. Clin. Invest. 1997, 100:1742-1749.
33. Pantos C., Mourouzis I., Tsagoulis N., Markakis K., Galanopoulos G., Roukounakis N., et al. Thyroid hormone at supra-physiological dose optimizes cardiac geometry and improves cardiac function in rats with old myocardial infarction. J. Physiol. Pharmacol. 2009, 60:49-56.
34. Pantos C., Mourouzis I., Cokkinos D.V. New insights into the role of thyroid hormone in cardiac remodeling: time to reconsider?. Heart Fail. Rev. 2011, 16:79-96.
35. Ungvari Z., Csiszar A. The emerging role of IGF-1 deficiency in cardiovascular aging: recent advances. J. Gerontol. A Biol. Sci. Med. Sci. 2012, 67:599-610.
36. Spallarossa P., Brunelli C., Minuto F., Caruso D., Battistini M., Caponnetto S., et al. Insulin-like growth factor-I and angiographically documented coronary artery disease. Am. J. Cardiol. 1996, 77:200-202.
37. Juul A., Scheike T., Davidsen M., Gyllenborg J., Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002, 106:939-944.
38. Conti E., Andreotti F., Sciahbasi A., Riccardi P., Marra G., Menini E., et al. Markedly reduced insulin-like growth factor-1 in the acute phase of myocardial infarction. J. Am. Coll. Cardiol. 2001, 38:26-32.
39. Vasan R.S., Sullivan L.M., D'Agostino R.B., Roubenoff R., Harris T., Sawyer D.B., et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham heart study. Ann. Intern. Med. 2003, 139:642-648.
40. Vinciguerra M., Santini M.P., Claycomb W.C., Ladurner A.G., Rosenthal N. Local IGF-1 isoform protects cardiomyocytes from hypertrophic and oxidative stresses via SirT1 activity. Aging (Albany NY) 2010, 2:43-62.
41. Vinciguerra M., Santini M.P., Martinez C., Pazienza V., Claycomb W.C., Giuliani A., et al. mIGF-1/JNK1/SirT1 signaling confers protection against oxidative stress in the heart. Aging Cell 2012, 11:139-149.
42. Takeda N., Manabe I., Uchino Y., Eguchi K., Matsumoto S., Nishimura S., et al. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J. Clin. Invest. 2010, 120:254-265.
43. Troncoso R., Ibarra C., Vicencio J.M., Jaimovich E., Lavandero S. New insights into IGF-1 signaling in the heart. Trends Endocrinol. Metab. 2014, 25:128-137.
44. Glass D.J. Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J. Biochem. Cell Biol. 2005, 37:1974-1984.
45. Song Y.H., Godard M., Li Y., Richmond S.R., Rosenthal N., Delafontaine P. Insulin-like growth factor I-mediated skeletal muscle hypertrophy is characterized by increased mTOR-p70S6K signaling without increased Akt phosphorylation. J. Investig. Med. 2005, 53:135-142.
46. Poehlman E.T., Rosen C.J., Copeland K.C. The influence of endurance training on insulin-like growth-factor-I in older individuals. Metabolism 1994, 43:1401-1405.
47. Serneri G.G.N., Boddi M., Modesti P.A., Cecioni I., Coppo M., Padeletti L., et al. Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes. Circ. Res. 2001, 89:977-982.
48. Liu J.P., Baker J., Perkins A.S., Robertson E.J., Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993, 75:59-72.
49. Powell-Braxton L., Hollingshead P., Warburton C., Dowd M., Pitts-Meek S., Dalton D., et al. IGF-I is required for normal embryonic growth in mice. Genes Dev. 1993, 7:2609-2617.
50. Delaughter M.C., Taffet G.E., Fiorotto M.L., Entman M.L., Schwartz R.J. Local insulin-like growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice. FASEB J. 1999, 13:1923-1929.
51. Reiss K., Cheng W., Ferber A., Kajstura J., Li P., Li B., et al. Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:8630-8635.
52. Ikeda H., Shiojima I., Ozasa Y., Yoshida M., Holzenberger M., Kahn C.R., et al. Interaction of myocardial insulin receptor and IGF receptor signaling in exercise-induced cardiac hypertrophy. J. Mol. Cell. Cardiol. 2009, 47:664-675.
53. Moellendorf S., Kessels C., Peiseler L., Raupach A., Jacoby C., Vogt N., et al. IGF-IR signaling attenuates the age-related decline of diastolic cardiac function. Am. J. Physiol. Endocrinol. Metab. 2012, 303:E213-E222.
54. Saltiel A.R., Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001, 414:799-806.
55. Tatar M., Bartke A., Antebi A. The endocrine regulation of aging by insulin-like signals. Science 2003, 299:1346-1351.
56. Kim Y.K., Kim S.J., Yatani A., Huang Y.H., Castelli G., Vatner D.E., et al. Mechanism of enhanced cardiac function in mice with hypertrophy induced by overexpressed Akt. J. Biol. Chem. 2003, 278:47622-47628.
57. Kemi O.J., Ceci M., Wisloff U., Grimaldi S., Gallo P., Smith G.L., et al. Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy. J. Cell. Physiol. 2008, 214:316-321.
58. Catalucci D., Zhang D.H., DeSantiago J., Aimond F., Barbara G., Chemin J., et al. Akt regulates L-type Ca2+ channel activity by modulating Ca-v alpha 1 protein stability. J. Cell Biol. 2009, 184:923-933.
59. Catalucci D., Latronico M.V.G., Ceci M., Rusconi F., Young H.S., Gallo P., et al. At increases sarcoplasmic reticulum Ca2+ cycling by direct phosphorylation of phospholamban at Thr(17). J. Biol. Chem. 2009, 284:28180-28187.
60. Boudina S., Bugger H., Sena S., O'Neill B.T., Zaha V.G., Ilkun O., et al. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation 2009, 119:1272-1283.
61. Sena S., Hu P., Zhang D., Wang X., Wayment B., Olsen C., et al. Impaired insulin signaling accelerates cardiac mitochondrial dysfunction after myocardial infarction. J. Mol. Cell. Cardiol. 2009, 46:910-918.
62. Araki E., Lipes M.A., Patti M.E., Bruning J.C., Haag B., Johnson R.S., et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 1994, 372:186-190.
63. Burks D.J., Font de Mora J., Schubert M., Withers D.J., Myers M.G., Towery H.H., et al. IRS-2 pathways integrate female reproduction and energy homeostasis. Nature 2000, 407:377-382.
64. Zhang D., Contu R., Latronico M.V., Zhang J., Rizzi R., Catalucci D., et al. MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J. Clin. Invest. 2010, 120:2805-2816.
65. Bostrom P., Mann N., Wu J., Quintero P.A., Plovie E.R., Panakova D., et al. C/EBPbeta controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell 2010, 143:1072-1083.
66. Condorelli G., Drusco A., Stassi G., Bellacosa A., Roncarati R., Iaccarino G., et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:12333-12338.
67. Matsui T., Li L., Wu J.C., Cook S.A., Nagoshi T., Picard M.H., et al. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J. Biol. Chem. 2002, 277:22896-22901.
68. Shioi T., McMullen J.R., Kang P.M., Douglas P.S., Obata T., Franke T.F., et al. Akt/protein kinase B promotes organ growth in transgenic mice. Mol. Cell. Biol. 2002, 22:2799-2809.
69. Yamashita K., Kajstura J., Discher D.J., Wasserlauf B.J., Bishopric N.H., Anversa P., et al. Reperfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts overexpressing insulin-like growth factor-1. Circ. Res. 2001, 88:609-614.
70. McMullen J.R., Shioi T., Zhang L., Tarnavski O., Sherwood M.C., Kang P.M., et al. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:12355-12360.
71. Shioi T., Kang P.M., Douglas P.S., Hampe J., Yballe C.M., Lawitts J., et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 2000, 19:2537-2548.
72. Wende A.R., O'Neill B.T., Bugger H., Riehle C., Tuinei J., Buchanan J., et al. Enhanced cardiac Akt/protein kinase B signaling contributes to pathological cardiac hypertrophy in part by impairing mitochondrial function via transcriptional repression of mitochondrion-targeted nuclear genes. Mol. Cell. Biol. 2015, 35:831-846.
73. Zwadlo C., Schmidtmann E., Szaroszyk M., Kattih B., Froese N., Hinz H., et al. Antiandrogenic therapy with finasteride attenuates cardiac hypertrophy and left ventricular dysfunction. Circulation 2015, 131:1071-1081.
74. Hebert A.S., Dittenhafer-Reed K.E., Yu W., Bailey D.J., Selen E.S., Boersma M.D., et al. Calorie restriction and SIRT3 trigger global reprogramming of the mitochondrial protein acetylome. Mol. Cell 2013, 49:186-199.
75. Kanfi Y., Shalman R., Peshti V., Pilosof S.N., Gozlan Y.M., Pearson K.J., et al. Regulation of SIRT6 protein levels by nutrient availability. FEBS Lett. 2008, 582:543-548.
76. Qiu X., Brown K., Hirschey M.D., Verdin E., Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab. 2010, 12:662-667.
77. Canto C., Auwerx J. Caloric restriction, SIRT1 and longevity. Trends Endocrinol. Metab. 2009, 20:325-331.
78. Bellizzi D., Rose G., Cavalcante P., Covello G., Dato S., De Rango F., et al. A novel VNTR enhancer within the SIRT3 gene, a human homologue of SIR2, is associated with survival at oldest ages. Genomics 2005, 85:258-263.
79. Kanfi Y., Naiman S., Amir G., Peshti V., Zinman G., Nahum L., et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature 2012, 483:218-221.
80. Fontana L., Partridge L., Longo V.D. Extending healthy life span-from yeast to humans. Science 2010, 328:321-326.
81. Baur J.A., Chen D., Chini E.N., Chua K., Cohen H.Y., de Cabo R., et al. Dietary restriction: standing up for sirtuins. Science 2010, 329:1012-1013. author reply 3-4.
82. Sundaresan N.R., Gupta M., Kim G., Rajamohan S.B., Isbatan A., Gupta M.P. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J. Clin. Invest. 2009, 119:2758-2771.
83. Pillai V.B., Sundaresan N.R., Kim G., Gupta M., Rajamohan S.B., Pillai J.B., et al. Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway. J. Biol. Chem. 2010, 285:3133-3144.
84. Sundaresan N.R., Vasudevan P., Zhong L., Kim G., Samant S., Parekh V., et al. The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun. Nat. Med. 2012, 18:1643-1650.
85. Alcendor R.R., Gao S., Zhai P., Zablocki D., Holle E., Yu X., et al. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ. Res. 2007, 100:1512-1521.
86. Oka S., Alcendor R., Zhai P., Park J.Y., Shao D., Cho J., et al. PPARalpha-Sirt1 complex mediates cardiac hypertrophy and failure through suppression of the ERR transcriptional pathway. Cell Metab. 2011, 14:598-611.
87. Potente M., Ghaeni L., Baldessari D., Mostoslavsky R., Rossig L., Dequiedt F., et al. SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev. 2007, 21:2644-2658.
88. Hill J.A., Olson E.N. Cardiac plasticity. N. Engl. J. Med. 2008, 358:1370-1380.
89. Sandler H., Dodge H.T. Left ventricular tension and stress in man. Circ. Res. 1963, 13:91-104.
90. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N. Engl. J. Med. 1990, 322:1561-1566.
91. Koren M.J., Devereux R.B., Casale P.N., Savage D.D., Laragh J.H. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann. Intern. Med. 1991, 114:345-352.
92. Zou Y., Hiroi Y., Uozumi H., Takimoto E., Toko H., Zhu W., et al. Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy. Circulation 2001, 104:97-101.
93. Ichihara S., Senbonmatsu T., Price E., Ichiki T., Gaffney F.A., Inagami T. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation 2001, 104:346-351.
94. Senbonmatsu T., Ichihara S., Price E., Gaffney F.A., Inagami T. Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. J. Clin. Invest. 2000, 106:R25-R29.
95. Hill J.A., Karimi M., Kutschke W., Davisson R.L., Zimmerman K., Wang Z., et al. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation 2000, 101:2863-2869.
96. van Berlo J.H., Maillet M., Molkentin J.D. Signaling effectors underlying pathologic growth and remodeling of the heart. J. Clin. Invest. 2013, 123:37-45.
97. Perrino C., Naga Prasad S.V., Mao L., Noma T., Yan Z., Kim H.S., et al. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J. Clin. Invest. 2006, 116:1547-1560.
98. Molkentin J.D., Lu J.R., Antos C.L., Markham B., Richardson J., Robbins J., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998, 93:215-228.
99. Wilkins B.J., Molkentin J.D. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem. Biophys. Res. Commun. 2004, 322:1178-1191.
100. Molkentin J.D., Lu J.R., Antos C.L., Markham B., Richardson J., Robbins J., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998, 93:215-228.
101. Houser S.R., Molkentin J.D. Does contractile Ca2+ control calcineurin-NFAT signaling and pathological hypertrophy in cardiac myocytes?. Sci. Signal. 2008, 1.
102. Wilkins B.J., Dai Y.S., Bueno OF, Parsons S.A., Xu J., Plank D.M., et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ. Res. 2004, 94:110-118.
103. Seth M., Zhang Z.S., Mao L., Graham V., Burch J., Stiber J., et al. TRPC1 channels are critical for hypertrophic signaling in the heart. Circ. Res. 2009, 105:1023-1030.
104. Kuwahara K., Wang Y., McAnally J., Richardson J.A., Bassel-Duby R., Hill J.A., et al. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. J. Clin. Invest. 2006, 116:3114-3126.
105. Niizeki T., Takeishi Y., Kitahara T., Arimoto T., Ishino M., Bilim O., et al. Diacylglycerol kinase-epsilon restores cardiac dysfunction under chronic pressure overload: a new specific regulator of Galpha(q) signaling cascade. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H245-H255.
106. Ohba T., Watanabe H., Murakami M., Takahashi Y., Iino K., Kuromitsu S., et al. Upregulation of TRPC1 in the development of cardiac hypertrophy. J. Mol. Cell. Cardiol. 2007, 42:498-507.
107. Wu X., Eder P., Chang B., Molkentin J.D. TRPC channels are necessary mediators of pathologic cardiac hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:7000-7005.
108. Cohn J.N. Plasma norepinephrine and mortality. Clin. Cardiol. 1995, 18:I9-12.
109. Strand A.H., Gudmundsdottir H., Os I., Smith G., Westheim A.S., Bjornerheim R., et al. Arterial plasma noradrenaline predicts left ventricular mass independently of blood pressure and body build in men who develop hypertension over 20 years. J. Hypertens. 2006, 24:905-913.
110. Packer M., Coats A.J., Fowler M.B., Katus H.A., Krum H., Mohacsi P., et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 2001, 344:1651-1658.
111. Poole-Wilson P.A., Swedberg K., Cleland J.G., Di Lenarda A., Hanrath P., Komajda M., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362:7-13.
112. Hoch B., Meyer R., Hetzer R., Krause E.G., Karczewski P. Identification and expression of delta-isoforms of the multifunctional Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human myocardium. Circ. Res. 1999, 84:713-721.
113. Kirchhefer U., Schmitz W., Scholz H., Neumann J. Activity of cAMP-dependent protein kinase and Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human hearts. Cardiovasc. Res. 1999, 42:254-261.
114. Ai X., Curran J.W., Shannon T.R., Bers D.M., Pogwizd S.M. Ca2+/calmodulin-dependent protein kinase modulates cardiac ryanodine receptor phosphorylation and sarcoplasmic reticulum Ca2+ leak in heart failure. Circ. Res. 2005, 97:1314-1322.
115. Bossuyt J., Helmstadter K., Wu X., Clements-Jewery H., Haworth R.S., Avkiran M., et al. Ca2+/calmodulin-dependent protein kinase IIdelta and protein kinase D overexpression reinforce the histone deacetylase 5 redistribution in heart failure. Circ. Res. 2008, 102:695-702.
116. Ling H., Zhang T., Pereira L., Means C.K., Cheng H., Gu Y., et al. Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. J. Clin. Invest. 2009, 119:1230-1240.
117. Backs J., Backs T., Neef S., Kreusser M.M., Lehmann L.H., Patrick D.M., et al. The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2342-2347.
118. Zhu W., Zou Y., Shiojima I., Kudoh S., Aikawa R., Hayashi D., et al. Ca2+/calmodulin-dependent kinase II and calcineurin play critical roles in endothelin-1-induced cardiomyocyte hypertrophy. J. Biol. Chem. 2000, 275:15239-15245.
119. Ramirez M.T., Zhao X.L., Schulman H., Brown J.H. The nuclear deltaB isoform of Ca2+/calmodulin-dependent protein kinase II regulates atrial natriuretic factor gene expression in ventricular myocytes. J. Biol. Chem. 1997, 272:31203-31208.
120. Sei C.A., Irons C.E., Sprenkle A.B., McDonough P.M., Brown J.H., Glembotski C.C. The alpha-adrenergic stimulation of atrial natriuretic factor expression in cardiac myocytes requires calcium influx, protein kinase C, and calmodulin-regulated pathways. J. Biol. Chem. 1991, 266:15910-15916.
121. Backs J., Song K., Bezprozvannaya S., Chang S., Olson E.N. CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J. Clin. Invest. 2006, 116:1853-1864.
122. Zhang C.L., McKinsey T.A., Chang S., Antos C.L., Hill J.A., Olson E.N. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002, 110:479-488.
123. Passier R., Zeng H., Frey N., Naya F.J., Nicol R.L., McKinsey T.A., et al. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J. Clin. Invest. 2000, 105:1395-1406.
124. Takimoto E., Champion H.C., Li M., Belardi D., Ren S., Rodriguez E.R., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat. Med. 2005, 11:214-222.
125. Kukreja R.C., Salloum F.N., Das A. Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. J. Am. Coll. Cardiol. 2012, 59:1921-1927.
126. van Heerebeek L., Hamdani N., Falcao-Pires I., Leite-Moreira A.F., Begieneman M.P., Bronzwaer J.G., et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 2012, 126:830-839.
127. Takimoto E., Koitabashi N., Hsu S., Ketner E.A., Zhang M., Nagayama T., et al. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J. Clin. Invest. 2009, 119:408-420.
128. Koitabashi N., Aiba T., Hesketh G.G., Rowell J., Zhang M., Takimoto E., et al. Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation novel mechanism of cardiac stress modulation by PDE5 inhibition. J. Mol. Cell. Cardiol. 2009, 48:713-724.
129. Lee D.I., Zhu G., Sasaki T., Cho G.S., Hamdani N., Holewinski R., et al. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature 2015, 519:472-476.
130. Arimoto T., Takeishi Y., Takahashi H., Shishido T., Niizeki T., Koyama Y., et al. Cardiac-specific overexpression of diacylglycerol kinase zeta prevents Gq protein-coupled receptor agonist-induced cardiac hypertrophy in transgenic mice. Circulation 2006, 113:60-66.
131. Takeishi Y., Ping P., Bolli R., Kirkpatrick D.L., Hoit B.D., Walsh R.A. Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy. Circ. Res. 2000, 86:1218-1223.
132. Gutkind J.S., Offermanns S. A new G(q)-initiated MAPK signaling pathway in the heart. Dev. Cell 2009, 16:163-164.
133. Haq S., Choukroun G., Lim H., Tymitz K.M., del Monte F., Gwathmey J., et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 2001, 103:670-677.
134. Toischer K., Rokita A.G., Unsold B., Zhu W., Kararigas G., Sossalla S., et al. Differential cardiac remodeling in preload versus afterload. Circulation 2010, 122:993-1003.
135. Bueno OF, De Windt L.J., Tymitz K.M., Witt S.A., Kimball T.R., Klevitsky R., et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 2000, 19:6341-6350.
136. Purcell N.H., Wilkins B.J., York A., Saba-El-Leil M.K., Meloche S., Robbins J., et al. Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14074-14079.
137. Kehat I., Davis J., Tiburcy M., Accornero F., Saba-El-Leil M.K., Maillet M., et al. Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circ. Res. 2011, 108:176-183.
138. Nishida K., Yamaguchi O., Hirotani S., Hikoso S., Higuchi Y., Watanabe T., et al. p38alpha mitogen-activated protein kinase plays a critical role in cardiomyocyte survival but not in cardiac hypertrophic growth in response to pressure overload. Mol. Cell. Biol. 2004, 24:10611-10620.
139. Liao P., Georgakopoulos D., Kovacs A., Zheng M., Lerner D., Pu H., et al. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:12283-12288.
140. Liang Q., Bueno OF, Wilkins B.J., Kuan C.Y., Xia Y., Molkentin J.D. c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling. EMBO J. 2003, 22:5079-5089.
141. Liu W., Zi M., Jin J., Prehar S., Oceandy D., Kimura T.E., et al. Cardiac-specific deletion of mkk4 reveals its role in pathological hypertrophic remodeling but not in physiological cardiac growth. Circ. Res. 2009, 104:905-914.
142. Bueno OF, De Windt L.J., Lim H.W., Tymitz K.M., Witt S.A., Kimball T.R., et al. The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo. Circ. Res. 2001, 88:88-96.
143. Auger-Messier M., Accornero F., Goonasekera S.A., Bueno OF, Lorenz J.N., van Berlo J.H., et al. Unrestrained p38 MAPK activation in Dusp1/4 double-null mice induces cardiomyopathy. Circ. Res. 2013, 112:48-56.
144. Samuelsson A.M., Bollano E., Mobini R., Larsson B.M., Omerovic E., Fu M., et al. Hyperinsulinemia: effect on cardiac mass/function, angiotensin II receptor expression, and insulin signaling pathways. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H787-H796.
145. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., Buse J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 2008, 358:2545-2559.
146. Sciarretta S., Zhai P.Y., Shao D., Maejima Y., Robbins J., Volpe M., et al. Rheb is a critical regulator of autophagy during myocardial ischemia pathophysiological implications in obesity and metabolic syndrome. Circulation 2012, 125. (1134-U166).
147. Ashrafian H., Frenneaux M.P., Opie L.H. Metabolic mechanisms in heart failure. Circulation 2007, 116:434-448.
148. Ingelsson E., Sundstrom J., Arnlov J., Zethelius B., Lind L. Insulin resistance and risk of congestive heart failure. J. Am. Med. Assoc. 2005, 294:334-341.
149. Witteles R.M., Tang W.H., Jamali A.H., Chu J.W., Reaven G.M., Fowler M.B. Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link. J. Am. Coll. Cardiol. 2004, 44:78-81.
150. Shimizu I., Yoshida Y., Katsuno T., Tateno K., Okada S., Moriya J., et al. p53-induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure. Cell Metab. 2012, 15:51-64.
151. Choi A.M., Ryter S.W., Levine B. Autophagy in human health and disease. N. Engl. J. Med. 2013, 368:651-662.
152. Yang L., Li P., Fu S., Calay E.S., Hotamisligil G.S. Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. Cell Metab. 2010, 11:467-478.
153. Singh R., Xiang Y., Wang Y., Baikati K., Cuervo A.M., Luu Y.K., et al. Autophagy regulates adipose mass and differentiation in mice. J. Clin. Invest. 2009, 119:3329-3339.
154. Zhang Y., Goldman S., Baerga R., Zhao Y., Komatsu M., Jin S. Adipose-specific deletion of autophagy-related gene 7 (atg7) in mice reveals a role in adipogenesis. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:19860-19865.
155. Matsui Y., Takagi H., Qu X., Abdellatif M., Sakoda H., Asano T., et al. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ. Res. 2007, 100:914-922.
156. Zhu H., Tannous P., Johnstone J.L., Kong Y., Shelton J.M., Richardson J.A., et al. Cardiac autophagy is a maladaptive response to hemodynamic stress. J. Clin. Invest. 2007, 117:1782-1793.
157. Nakai A., Yamaguchi O., Takeda T., Higuchi Y., Hikoso S., Taniike M., et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat. Med. 2007, 13:619-624.
158. Zaglia T., Milan G., Ruhs A., Franzoso M., Bertaggia E., Pianca N., et al. Atrogin-1 deficiency promotes cardiomyopathy and premature death via impaired autophagy. J. Clin. Invest. 2014, 124:2410-2424.
159. Gusterson R.J., Jazrawi E., Adcock I.M., Latchman D.S. The transcriptional co-activators CREB-binding protein (CBP) and p300 play a critical role in cardiac hypertrophy that is dependent on their histone acetyltransferase activity. J. Biol. Chem. 2003, 278:6838-6847.
160. Yanazume T., Hasegawa K., Morimoto T., Kawamura T., Wada H., Matsumori A., et al. Cardiac p300 is involved in myocyte growth with decompensated heart failure. Mol. Cell. Biol. 2003, 23:3593-3606.
161. Miyamoto S., Kawamura T., Morimoto T., Ono K., Wada H., Kawase Y., et al. Histone acetyltransferase activity of p300 is required for the promotion of left ventricular remodeling after myocardial infarction in adult mice in vivo. Circulation 2006, 113:679-690.
162. Lu J., McKinsey T.A., Nicol R.L., Olson E.N. Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:4070-4075.
163. Chang S., McKinsey T.A., Zhang C.L., Richardson J.A., Hill J.A., Olson E.N. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol. Cell. Biol. 2004, 24:8467-8476.
164. Hohl M., Wagner M., Reil J.C., Muller S.A., Tauchnitz M., Zimmer A.M., et al. HDAC4 controls histone methylation in response to elevated cardiac load. J. Clin. Invest. 2013, 123:1359-1370.
165. Trivedi C.M., Luo Y., Yin Z., Zhang M., Zhu W., Wang T., et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat. Med. 2007, 13:324-331.
166. Movassagh M., Choy M.K., Knowles D.A., Cordeddu L., Haider S., Down T., et al. Distinct epigenomic features in end-stage failing human hearts. Circulation 2011, 124:2411-2422.
167. Haider S., Cordeddu L., Robinson E., Movassagh M., Siggens L., Vujic A., et al. The landscape of DNA repeat elements in human heart failure. Genome Biol. 2012, 13:R90.
168. Kozomara A., Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2011, 39:D152-D157.
169. van Rooij E., Sutherland L.B., Liu N., Williams A.H., McAnally J., Gerard R.D., et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:18255-18260.
170. Ucar A., Gupta S.K., Fiedler J., Erikci E., Kardasinski M., Batkai S., et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat. Commun. 2012, 3:1078.
171. Callis T.E., Pandya K., Seok H.Y., Tang R.H., Tatsuguchi M., Huang Z.P., et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J. Clin. Invest. 2009, 119:2772-2786.
172. Matkovich S.J., Van Booven D.J., Youker K.A., Torre-Amione G., Diwan A., Eschenbacher W.H., et al. Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation 2009, 119:1263-1271.
173. Xu X.D., Song X.W., Li Q., Wang G.K., Jing Q., Qin Y.W. Attenuation of microRNA-22 derepressed PTEN to effectively protect rat cardiomyocytes from hypertrophy. J. Cell. Physiol. 2012, 227:1391-1398.
174. Gurha P., Abreu-Goodger C., Wang T., Ramirez M.O., Drumond A.L., van Dongen S., et al. Targeted deletion of microRNA-22 promotes stress-induced cardiac dilation and contractile dysfunction. Circulation 2012, 125:2751-2761.
175. Kumarswamy R., Thum T. Non-coding RNAs in cardiac remodeling and heart failure. Circ. Res. 2013, 113:676-689.
176. Melman Y.F., Shah R., Das S. MicroRNAs in heart failure: is the picture becoming less miRky?. Circ Heart Fail. 2014, 7:203-214.
177. Doenst T., Nguyen T.D., Abel E.D. Cardiac metabolism in heart failure: implications beyond ATP production. Circ. Res. 2013, 113:709-724.
178. Osorio J.C., Stanley W.C., Linke A., Castellari M., Diep Q.N., Panchal A.R., et al. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 2002, 106:606-612.
179. Kato T., Niizuma S., Inuzuka Y., Kawashima T., Okuda J., Tamaki Y., et al. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ. Heart Fail. 2010, 3:420-430.
180. Doenst T., Pytel G., Schrepper A., Amorim P., Farber G., Shingu Y., et al. Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. Cardiovasc. Res. 2010, 86:461-470.
181. Rosenblatt-Velin N., Montessuit C., Papageorgiou I., Terrand J., Lerch R. Postinfarction heart failure in rats is associated with upregulation of GLUT-1 and downregulation of genes of fatty acid metabolism. Cardiovasc. Res. 2001, 52:407-416.
182. Heather L.C., Cole M.A., Lygate C.A., Evans R.D., Stuckey D.J., Murray A.J., et al. Fatty acid transporter levels and palmitate oxidation rate correlate with ejection fraction in the infarcted rat heart. Cardiovasc. Res. 2006, 72:430-437.
183. Sack M.N., Rader T.A., Park S., Bastin J., McCune S.A., Kelly D.P. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 1996, 94:2837-2842.
184. Opie L.H., Knuuti J. The adrenergic-fatty acid load in heart failure. J. Am. Coll. Cardiol. 2009, 54:1637-1646.
185. Raher M.J., Thibault H.B., Buys E.S., Kuruppu D., Shimizu N., Brownell A.L., et al. A short duration of high-fat diet induces insulin resistance and predisposes to adverse left ventricular remodeling after pressure overload. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H2495-H2502.
186. Okere I.C., Chess D.J., McElfresh T.A., Johnson J., Rennison J., Ernsberger P., et al. High-fat diet prevents cardiac hypertrophy and improves contractile function in the hypertensive dahl salt-sensitive rat. Clin. Exp. Pharmacol. Physiol. 2005, 32:825-831.
187. Tuunanen H., Engblom E., Naum A., Nagren K., Hesse B., Airaksinen K.E., et al. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 2006, 114:2130-2137.
188. Randle P.J. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab. Rev. 1998, 14:263-283.
189. Jullig M., Hickey A.J., Chai C.C., Skea G.L., Middleditch M.J., Costa S., et al. Is the failing heart out of fuel or a worn engine running rich? A study of mitochondria in old spontaneously hypertensive rats. Proteomics 2008, 8:2556-2572.
190. Degens H., de Brouwer K.F., Gilde A.J., Lindhout M., Willemsen P.H., Janssen B.J., et al. Cardiac fatty acid metabolism is preserved in the compensated hypertrophic rat heart. Basic Res. Cardiol. 2006, 101:17-26.
191. Eberli F.R., Apstein C.S., Ngoy S., Lorell B.H. Exacerbation of left-ventricular ischemic diastolic dysfunction by pressure-overload hypertrophy - modification by specific-inhibition of cardiac angiotensin converting enzyme. Circ. Res. 1992, 70:931-943.
192. Zhabyeyev P., Gandhi M., Mori J., Basu R., Kassiri Z., Clanachan A., et al. Pressure-overload-induced heart failure induces a selective reduction in glucose oxidation at physiological afterload. Cardiovasc. Res. 2013, 97:676-685.
193. Christe M.E., Rodgers R.L. Altered glucose and fatty acid oxidation in hearts of the spontaneously hypertensive rat. J. Mol. Cell. Cardiol. 1994, 26:1371-1375.
194. Amorim P.A., Nguyen T.D., Shingu Y., Schwarzer M., Mohr F.W., Schrepper A., et al. Myocardial infarction in rats causes partial impairment in insulin response associated with reduced fatty acid oxidation and mitochondrial gene expression. J. Thorac. Cardiovasc. Surg. 2010, 140:1160-1167.
195. Davila-Roman V.G., Vedala G., Herrero P., de las Fuentes L., Rogers J.G., Kelly D.P., et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. 2002, 40:271-277.
196. Pereira R.O., Wende A.R., Olsen C., Soto J., Rawlings T., Zhu Y., et al. GLUT1 deficiency in cardiomyocytes does not accelerate the transition from compensated hypertrophy to heart failure. J. Mol. Cell. Cardiol. 2014, 72:95-103.
197. Pereira R.O., Wende A.R., Olsen C., Soto J., Rawlings T., Zhu Y., et al. Inducible overexpression of GLUT1 prevents mitochondrial dysfunction and attenuates structural remodeling in pressure overload but does not prevent left ventricular dysfunction. J. Am. Heart Assoc. 2013, 2.
198. Abel E.D., Kaulbach H.C., Tian R., Hopkins J.C., Duffy J., Doetschman T., et al. Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J. Clin. Invest. 1999, 104:1703-1714.
199. Schisler J.C., Grevengoed T.J., Pascual F., Cooper D.E., Ellis J.M., Paul D.S., et al. Cardiac energy dependence on glucose increases metabolites related to glutathione and activates metabolic genes controlled by mechanistic target of rapamycin. J. Am. Heart Assoc. 2015, 4.
200. Mirtschink P., Krishnan J., Grimm F., Sarre A., Horl M., Kayikci M., et al. HIF-driven SF3B1 induces KHK-C to enforce fructolysis and heart disease. Nature 2015, 522:444-449.
201. Banerjee I., Fuseler J.W., Price R.L., Borg T.K., Baudino T.A. Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H1883-H1891.
202. Vliegen H.W., van der Laarse A., Cornelisse C.J., Eulderink F. Myocardial changes in pressure overload-induced left ventricular hypertrophy. A study on tissue composition, polyploidization and multinucleation. Eur. Heart J. 1991, 12:488-494.
203. Leask A. Getting to the heart of the matter new insights into cardiac fibrosis. Circ. Res. 2015, 116:1269-1276.
204. Gregor M., Osmanagic-Myers S., Burgstaller G., Wolfram M., Fischer I., Walko G., et al. Mechanosensing through focal adhesion-anchored intermediate filaments. FASEB J. 2014, 28:715-729.
205. MacKenna D., Summerour S.R., Villarreal F.J. Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. Cardiovasc. Res. 2000, 46:257-263.
206. Moore-Morris T., Guimaraes-Camboa N., Banerjee I., Zambon A.C., Kisseleva T., Velayoudon A., et al. Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. J. Clin. Invest. 2014, 124:2921-2934.
207. Bogoyevitch M.A., Glennon P.E., Andersson M.B., Lazou A., Marshall C.J., Sugden P.H. Acidic fibroblast growth factor or endothelin-1 stimulate the MAP kinase cascade in cardiac myocytes. Biochem. Soc. Trans. 1993, 21:358S.
208. Pellieux C., Foletti A., Peduto G., Aubert J.F., Nussberger J., Beermann F., et al. Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J. Clin. Invest. 2001, 108:1843-1851.
209. Schultz J.E., Witt S.A., Nieman M.L., Reiser P.J., Engle S.J., Zhou M., et al. Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. J. Clin. Invest. 1999, 104:709-719.
210. Hayata N., Fujio Y., Yamamoto Y., Iwakura T., Obana M., Takai M., et al. Connective tissue growth factor induces cardiac hypertrophy through Akt signaling. Biochem. Biophys. Res. Commun. 2008, 370:274-278.
211. Panek A.N., Posch M.G., Alenina N., Ghadge S.K., Erdmann B., Popova E., et al. Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload. PLoS ONE 2009, 4.
212. Bang C., Batkai S., Dangwal S., Gupta S.K., Foinquinos A., Holzmann A., et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J. Clin. Invest. 2014, 124:2136-2146.
213. Kuwahara F., Kai H., Tokuda K., Kai M., Takeshita A., Egashira K., et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002, 106:130-135.
214. Teekakirikul P., Eminaga S., Toka O., Alcalai R., Wang L.B., Wakimoto H., et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-beta. J. Clin. Invest. 2010, 120:3520-3529.
215. Zhang D., Gaussin V., Taffet G.E., Belaguli N.S., Yamada M., Schwartz R.J., et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat. Med. 2000, 6:556-563.
216. Ono K., Ohtomo T., Ninomiya-Tsuji J., Tsuchiya M. A dominant negative TAK1 inhibits cellular fibrotic responses induced by TGF-beta. Biochem. Biophys. Res Commun. 2003, 307:332-337.
217. Tsuruda T., Kato J., Kitamura K., Kawamoto M., Kuwasako K., Imamura T., et al. An autocrine or a paracrine role of adrenomedullin in modulating cardiac fibroblast growth. Cardiovasc. Res. 1999, 43:958-967.
218. Niu P., Shindo T., Iwata H., Iimuro S., Takeda N., Zhang Y.L., et al. Protective effects of endogenous adrenomedullin on cardiac hypertrophy, fibrosis, and renal damage. Circulation 2004, 109:1789-1794.
219. Sanada S., Hakuno D., Higgins L.J., Schreiter E.R., McKenzie A.N.J., Lee R.T. IL-33 and ST2 comprise a critical biomechanically induced and card ioprotective signaling system. J. Clin. Invest. 2007, 117:1538-1549.
220. Kuhn M. Cardiology: a big-hearted molecule. Nature 2015, 519:416-417.
221. Lemmens K., Doggen K., De Keulenaer G.W. Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation 2007, 116:954-960.
222. Parodi E.M., Kuhn B. Signalling between microvascular endothelium and cardiomyocytes through neuregulin. Cardiovasc. Res. 2014, 102:194-204.
223. Scimia M.C., Hurtado C., Ray S., Metzler S., Wei K., Wang J., et al. APJ acts as a dual receptor in cardiac hypertrophy. Nature 2012, 488:394-398.
224. Ito H., Hirata Y., Hiroe M., Tsujino M., Adachi S., Takamoto T., et al. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ. Res. 1991, 69:209-215.
225. Ito H., Hiroe M., Hirata Y., Fujisaki H., Adachi S., Akimoto H., et al. Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation 1994, 89:2198-2203.
226. Heiden S., Vignon-Zellweger N., Masuda S., Yagi K., Nakayama K., Yanagisawa M., et al. Vascular endothelium derived endothelin-1 is required for normal heart function after chronic pressure overload in mice. PLoS ONE 2014, 9.
227. Epelman S., Lavine K.J., Beaudin A.E., Sojka D.K., Carrero J.A., Calderon B., et al. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Immunity 2013, 40:91-104.
228. Zandbergen H.R., Sharma U.C., Gupta S., Verjans J.W., van den Borne S., Pokharel S., et al. Macrophage depletion in hypertensive rats accelerates development of cardiomyopathy. J. Cardiovasc. Pharmacol. Ther. 2009, 14:68-75.
229. Haudek S.B., Cheng J., Du J., Wang Y., Hermosillo-Rodriguez J., Trial J., et al. Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy. J. Mol. Cell. Cardiol. 2010, 49:499-507.
230. Odegaard J.I., Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 2013, 339:172-177.
231. Lumeng C.N., Bodzin J.L., Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 2007, 117:175-184.
232. Frieler R.A., Mortensen R.M. Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation 2015, 131:1019-1030.
233. Devaux B., Scholz D., Hirche A., Klovekorn W.P., Schaper J. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur. Heart J. 1997, 18:470-479.
234. Kayama Y., Minamino T., Toko H., Sakamoto M., Shimizu I., Takahashi H., et al. Cardiac 12/15 lipoxygenase-induced inflammation is involved in heart failure. J. Exp. Med. 2009, 206:1565-1574.
235. Frangogiannis N.G., Smith C.W., Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc. Res. 2002, 53:31-47.
236. Nagai T., Anzai T., Kaneko H., Mano Y., Anzai A., Maekawa Y., et al. C-reactive protein overexpression exacerbates pressure overload-induced cardiac remodeling through enhanced inflammatory response. Hypertension 2011, 57:208-215.
237. Schilling J.D., Machkovech H.M., Kim A.H., Schwendener R., Schaffer J.E. Macrophages modulate cardiac function in lipotoxic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 2012, 303:H1366-H1373.
238. Rosenkranz S., Flesch M., Amann K., Haeuseler C., Kilter H., Seeland U., et al. Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am. J. Physiol. Heart Circ. Physiol. 2002, 283:H1253-H1262.
239. Kubota T., McTiernan C.F., Frye C.S., Slawson S.E., Lemster B.H., Koretsky A.P., et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ. Res. 1997, 81:627-635.
240. Sun M., Chen M., Dawood F., Zurawska U., Li J.Y., Parker T., et al. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 2007, 115:1398-1407.
241. Papathanasiou S., Rickelt S., Soriano M.E., Schips T.G., Maier H.J., Davos C.H., et al. Tumor necrosis factor-alpha confers cardioprotection through ectopic expression of keratins K8 and K18. Nat. Med. 2015, 21:1076-1084.
242. Hirota H., Yoshida K., Kishimoto T., Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:4862-4866.
243. Melendez G.C., McLarty J.L., Levick S.P., Du Y., Janicki J.S., Brower G.L. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 2010, 56:225-231.
244. Coles B., Fielding C.A., Rose-John S., Scheller J., Jones S.A., O'Donnell V.B. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. Am. J. Pathol. 2007, 171:315-325.
245. Ma F., Li Y., Jia L., Han Y., Cheng J., Li H., et al. Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF beta/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS ONE 2012, 7.
246. Meier H., Bullinger J., Marx G., Deten A., Horn L.C., Rassler B., et al. Crucial role of interleukin-6 in the development of norepinephrine-induced left ventricular remodeling in mice. Cell. Physiol. Biochem. 2009, 23:327-334.
247. Terrell A.M., Crisostomo P.R., Wairiuko G.M., Wang M., Morrell E.D., Meldrum D.R. Jak/STAT/SOCS signaling circuits and associated cytokine-mediated inflammation and hypertrophy in the heart. Shock 2006, 26:226-234.
248. Hirota H., Chen J., Betz U.A., Rajewsky K., Gu Y., Ross J., et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 1999, 97:189-198.
249. Honsho S., Nishikawa S., Amano K., Zen K., Adachi Y., Kishita E., et al. Pressure-mediated hypertrophy and mechanical stretch induces IL-1 release and subsequent IGF-1 generation to maintain compensative hypertrophy by affecting Akt and JNK pathways. Circ. Res. 2009, 105:1149-1158.
250. Van Tassell B.W., Arena R.A., Toldo S., Mezzaroma E., Azam T., Seropian I.M., et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS ONE 2012, 7.
251. Rajapurohitam V., Kilic A., Javadov S., Karmazyn M. Role of NF-kappaB and p38 MAPK activation in mediating angiotensin II and endothelin-1-induced stimulation in leptin production and cardiomyocyte hypertrophy. Mol. Cell. Biochem. 2012, 366:287-297.
252. Javan H., Szucsik A.M., Li L., Schaaf C.L., Salama M.E., Selzman C.H. Cardiomyocyte p65 nuclear factor-kappaB is necessary for compensatory adaptation to pressure overload. Circ. Heart Fail. 2015, 8:109-118.
253. Liu Q., Chen Y., Auger-Messier M., Molkentin J.D. Interaction between NFkappaB and NFAT coordinates cardiac hypertrophy and pathological remodeling. Circ. Res. 2012, 110:1077-1086.
254. Verma S.K., Krishnamurthy P., Barefield D., Singh N., Gupta R., Lambers E., et al. Interleukin-10 treatment attenuates pressure overload-induced hypertrophic remodeling and improves heart function via signal transducers and activators of transcription 3-dependent inhibition of nuclear factor-kappa B. Circulation 2012, 126. (418-+).
255. Yang F.M.Y., Dong A.P., Mueller P., Caicedo J., Sutton A.M., Odetunde J., et al. Coronary artery remodeling in a model of left ventricular pressure overload is influenced by platelets and inflammatory cells. PLoS ONE 2012, 7.
256. Ghigo A., Franco I., Morello F., Hirsch E. Myocyte signalling in leucocyte recruitment to the heart. Cardiovasc. Res. 2014, 102:270-280.
257. Kamo T., Akazawa H., Komuro I. Cardiac nonmyocytes in the hub of cardiac hypertrophy. Circ. Res. 2015, 117:89-98.
258. Hudlicka O., Brown M., Egginton S. Angiogenesis in skeletal and cardiac muscle. Physiol. Rev. 1992, 72:369-417.
259. Marcus M.L., Koyanagi S., Harrison D.G., Doty D.B., Hiratzka L.F., Eastham C.L. Abnormalities in the coronary circulation that occur as a consequence of cardiac hypertrophy. Am. J. Med. 1983, 75:62-66.
260. Tomanek R.J. Response of the coronary vasculature to myocardial hypertrophy. J. Am. Coll. Cardiol. 1990, 15:528-533.
261. Shimizu I., Aprahamian T., Kikuchi R., Shimizu A., Papanicolaou K.N., MacLauchlan S., et al. Vascular rarefaction mediates whitening of brown fat in obesity. J. Clin. Invest. 2014, 124:2099-2112.
262. Kitamoto Y., Tokunaga H., Tomita K. Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis. J. Clin. Invest. 1997, 99:2351-2357.
263. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 2004, 25:581-611.
264. Izumiya Y., Shiojima I., Sato K., Sawyer D.B., Colucci W.S., Walsh K. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 2006, 47:887-893.
265. Dass S., Holloway C.J., Cochlin L.E., Rider O.J., Mahmod M., Robson M., et al. No evidence of myocardial oxygen deprivation in nonischemic heart failure. Circ. Heart Fail. 2015, 8:1088-1093.
266. Heineke J., Auger-Messier M., Xu J., Oka T., Sargent M.A., York A., et al. Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart. J. Clin. Invest. 2007, 117:3198-3210.
267. Belaguli N.S., Sepulveda J.L., Nigam V., Charron F., Nemer M., Schwartz R.J. Cardiac tissue enriched factors serum response factor and GATA-4 are mutual coregulators. Mol. Cell. Biol. 2000, 20:7550-7558.
268. Liang Q., Wiese R.J., Bueno OF, Dai Y.S., Markham B.E., Molkentin J.D. The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1- and 2-mediated phosphorylation of serine 105 in cardiomyocytes. Mol. Cell. Biol. 2001, 21:7460-7469.
269. Ackah E., Yu J., Zoellner S., Iwakiri Y., Skurk C., Shibata R., et al. Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. J. Clin. Invest. 2005, 115:2119-2127.
270. Hur J., Yoon C.H., Lee C.S., Kim T.Y., Oh I.Y., Park K.W., et al. Akt is a key modulator of endothelial progenitor cell trafficking in ischemic muscle. Stem Cells 2007, 25:1769-1778.
271. Fulton D., Gratton J.P., McCabe T.J., Fontana J., Fujio Y., Walsh K., et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999, 399:597-601.
272. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999, 399:601-605.
273. Rikitake Y., Hirata K., Kawashima S., Ozaki M., Takahashi T., Ogawa W., et al. Involvement of endothelial nitric oxide in sphingosine-1-phosphate-induced angiogenesis. Arterioscler. Thromb. Vasc. Biol. 2002, 22:108-114.
274. Tirziu D., Chorianopoulos E., Moodie K.L., Palac R.T., Zhuang Z.W., Tjwa M., et al. Myocardial hypertrophy in the absence of external stimuli is induced by angiogenesis in mice. J. Clin. Invest. 2007, 117:3188-3197.
275. Jaba I.M., Zhuang Z.W., Li N., Jiang Y., Martin K.A., Sinusas A.J., et al. NO triggers RGS4 degradation to coordinate angiogenesis and cardiomyocyte growth. J. Clin. Invest. 2013, 123:1718-1731.
276. Givertz M.M. Cardiology patient page: peripartum cardiomyopathy. Circulation 2013, 127:e622-e626.
277. Patten I.S., Rana S., Shahul S., Rowe G.C., Jang C., Liu L., et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 2012, 485:333-338.
278. Tsagalou E.P., Anastasiou-Nana M., Agapitos E., Gika A., Drakos S.G., Terrovitis J.V., et al. Depressed coronary flow reserve is associated with decreased myocardial capillary density in patients with heart failure due to idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. 2008, 52:1391-1398.
279. Drakos S.G., Kfoury A.G., Hammond E.H., Reid B.B., Revelo M.P., Rasmusson B.Y., et al. Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart. J. Am. Coll. Cardiol. 2010, 56:382-391.
280. Borlaug B.A. The pathophysiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. 2014, 11:507-515.
281. Lloyd-Jones D., Adams R.J., Brown T.M., Carnethon M., Dai S., De Simone G., et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121:e46-e215.
282. Mohammed S.F., Hussain S., Mirzoyev S.A., Edwards W.D., Maleszewski J.J., Redfield M.M. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 2015, 131:550-559.
283. Lakatta E.G. Cardiovascular regulatory mechanisms in advanced age. Physiol. Rev. 1993, 73:413-467.
284. Shih H., Lee B., Lee R.J., Boyle A.J. The aging heart and post-infarction left ventricular remodeling. J. Am. Coll. Cardiol. 2011, 57:9-17.
285. Prasun K., Das R.T., Panagia V., Dhalla N.S. β-adrenergic signal transduction pathway in developing and aging hearts. Heart Fail. Rev. 1997, 23-41.
286. Loffredo F.S., Steinhauser M.L., Jay S.M., Gannon J., Pancoast J.R., Yalamanchi P., et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell 2013, 153:828-839.
287. Smith S.C., Zhang X.X., Zhang X.Y., Gross P., Starosta T., Mohsin S., et al. GDF11 does not rescue aging-related pathological hypertrophy. Circ. Res. 2015, 117:926-932.
288. Katsimpardi L., Litterman N.K., Schein P.A., Miller C.M., Loffredo F.S., Wojtkiewicz G.R., et al. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science 2014, 344:630-634.